TKNOMEDIUM SIGNALFINANCIAL10-K

TKNO showed significant operational improvement with gross profit nearly doubling and losses narrowing substantially, while removing references to workforce reductions and specific geopolitical conflicts.

The company appears to be successfully executing a turnaround with dramatic gross profit improvement (+85.9%) and meaningful reduction in operating losses (+35.1%), suggesting better operational efficiency and cost management. The removal of workforce reduction risk language indicates management may have stabilized the organization, though the company remains unprofitable and stockholders' equity declined significantly.

Comparing 2026-03-02 vs 2025-03-07View on EDGAR →
FINANCIAL ANALYSIS

TKNO demonstrated strong operational progress with gross profit nearly doubling to $13.4M and net losses narrowing from -$26.7M to -$17.3M, while operating cash flow improved 30% though remaining negative. The balance sheet shows mixed signals with cash increasing 59% to $5.9M and current liabilities decreasing 33%, but stockholders' equity declined 16.5% and debt increased 39%, suggesting potential dilution or financing needs. Overall, the financials indicate meaningful operational improvements but continued cash burn and weakening equity position require monitoring.

FINANCIAL STATEMENT CHANGES
Gross Profit
P&L
+85.9%
$7.2M$13.4M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Cash & Equivalents
Balance Sheet
+59.4%
$3.7M$5.9M

Cash position surged 59.4% — strong cash generation or capital raise providing significant financial cushion.

Total Debt
Balance Sheet
+39%
$9.4M$13.1M

Debt increased 39% — substantial leverage increase; assess whether deployed for growth or covering losses.

Net Income
P&L
+35.5%
-$26.7M-$17.3M

Net income grew 35.5% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+35.1%
-$26.1M-$17.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Current Liabilities
Balance Sheet
-32.8%
$11.2M$7.5M

Current liabilities reduced — improved short-term financial position and working capital health.

Operating Cash Flow
Cash Flow
+30.2%
-$12.4M-$8.6M

Operating cash flow surged 30.2% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
-20.4%
$2.8M$2.2M

R&D spending cut 20.4% — could signal cost discipline or concerning reduction in innovation investment.

Current Assets
Balance Sheet
-19.3%
$42.8M$34.5M

Current assets declined 19.3% — monitor working capital adequacy and short-term liquidity.

Stockholders Equity
Balance Sheet
-16.5%
$82.4M$68.8M

Equity decreased 16.5% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-03-07
ADDED
We have invested a significant amount of capital in our manufacturing facilities.
Natural disasters (including earthquakes, fire, and drought), geopolitical unrest, war, terrorism, public health issues or other catastrophic events, some possibly related to the increasing effects of climate change, could disrupt the supply, production, delivery, or demand of our products, which could negatively affect our operations and performance.
Food and Drug Administration (FDA) has approved a number of cell and gene therapies in the U.S.
as has the European Union (EU) according to reports from the Alliance for Regenerative Medicine.
The cell and gene therapy sector continued to see regulatory approvals throughout 2025 both in the U.S.
+7 more — sign up free →
REMOVED
We have invested a significant amount of capital in our new and legacy manufacturing facilities.
Natural disasters (including earthquakes, fire, and drought), geopolitical unrest, war (including the war in Ukraine and the Israeli-Hamas war), terrorism, public health issues (like the COVID-19 pandemic) or other catastrophic events, some possibly related to the increasing effects of climate change, could disrupt the supply, production, delivery, or demand of our products, which could negatively affect our operations and performance.
We face risks arising from our recent workforce reductions, including adverse effects on employee morale, risks to our ability to meet customer demand with adequate turnaround times, and uncertainty around our ability to sustain cost savings from the workforce reductions.
Food and Drug Administration (FDA) approved five gene therapies for rare genetic diseases.
Meanwhile, 2023 was a breakthrough year for cell and gene therapies, with seven FDA approvals in the U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →